Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

From 2006 until its acquisition in April 2011, Mr. Ballantyne served as Executive Vice President and Chief Financial Officer of Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. for $1.3 billion. While at Clinical Data, Mr. Ballantyne was instrumental in leading corporate financings totaling approximately $220 million as well as a number of acquisition and divestitures totaling $116 million.

"We are very pleased to welcome Evan to the Adeona leadership team. Evan's significant financial, strategic and operating experience in the biopharmaceutical sector will be valuable assets to the Company, as we continue to build Adeona's portfolio of synthetic biologics and DNA-based human therapeutics," stated Jeff Riley, Chief Executive Officer, President and Chairman at Adeona. "With Evan's exceptionally strong track record in finance and management, I look forward to working closely with him to continue to strengthen the Company and increase shareholder value."

Mr. Ballantyne has also served as Chief Financial Officer of a number of private medical technology companies, including Avedro and ZymeQuest. Earlier in his career, Mr. Ballantyne served as Vice President and Chief Operating Officer for ACNielsen Europe Middle East & Africa and held the Chief Financial Officer position as well for two years. There, he was responsible for all aspects of operations, strategic planning and finance in more than 45 countries for a corporation with 9,700 employees. He also helped lead the company's successful ISO certification process. Mr. Ballantyne began his career at the Dun & Bradstreet Corporation where he held several senior financial positions.

Mr. Ballantyne earned a B.A. from the University of Western Ontario, and took a post-graduate degree in Business Administration with Honors from the University of Windsor.